Thursday, June 23rd, 2011
By Reuters
WASHINGTON (Reuters) - The Supreme Court struck down on Thursday a state law that prohibits the use of prescription drug records for marketing, in a case pitting free-speech rights against medical privacy concerns.
The high court handed a victory to data mining companies IMS Health, Verispan and Source Healthcare Analytics, a unit of Dutch publisher Wolters Kluwer, that collect and sell such information and that challenged the law.
(Reporting by James Vicini, editing by Gerald E. McCormick)
Thursday, June 23rd, 2011
WASHINGTON (Reuters) - The Supreme Court ruled on Thursday that generic drug companies cannot be sued under state law over allegations that they failed to provide adequate label warnings about potential side effects.
The justices handed a victory to Israel's Teva Pharmaceutical Industries Ltd, Mylan Inc's UDL Laboratories and Iceland-based Actavis Inc by overturning U.S. appeals court rulings that allowed such lawsuits.
(Reporting by James Vicini, Editing by Gerald E. McCormick)
By Reuters
WASHINGTON (Reuters) - The Supreme Court struck down on Thursday a state law that prohibits the use of prescription drug records for marketing, in a case pitting free-speech rights against medical privacy concerns.
The high court handed a victory to data mining companies IMS Health, Verispan and Source Healthcare Analytics, a unit of Dutch publisher Wolters Kluwer, that collect and sell such information and that challenged the law.
(Reporting by James Vicini, editing by Gerald E. McCormick)
Thursday, June 23rd, 2011
WASHINGTON (Reuters) - The Supreme Court ruled on Thursday that generic drug companies cannot be sued under state law over allegations that they failed to provide adequate label warnings about potential side effects.
The justices handed a victory to Israel's Teva Pharmaceutical Industries Ltd, Mylan Inc's UDL Laboratories and Iceland-based Actavis Inc by overturning U.S. appeals court rulings that allowed such lawsuits.
(Reporting by James Vicini, Editing by Gerald E. McCormick)
No comments:
Post a Comment